<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD03180000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P35372</UniProt_ID>
  <Seq_Length>400</Seq_Length>
  <Molecule_Weight>44779</Molecule_Weight>
  <KEGG_ID>hsa:4988</KEGG_ID>
  <Orthology_ID>K04215</Orthology_ID>
  <EBI_ID>EBI-2624570</EBI_ID>
  <Function_Summary>Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.</Function_Summary>
  <Pfam_ID>PF00001:7tm_1</Pfam_ID>
  <Allosteric_Activator_Count>1</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>4</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Hmop</Alias>
      <Alias>M-OR-1</Alias>
      <Alias>MOR-1</Alias>
      <Alias>Mu opiate receptor</Alias>
      <Alias>Mu opioid receptor</Alias>
      <Alias>MOP</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Combining with beta-endorphin to initiate a change in cell activity.</Detail>
      <Keyword>Beta-endorphin receptor activity</Keyword>
      <Ontology_ID>GO:0004979</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a G-protein alpha subunit. The alpha subunit binds a guanine nucleotide.</Detail>
      <Keyword>G-protein alpha-subunit binding</Keyword>
      <Ontology_ID>GO:0001965</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an opioid to initiate a change in cell activity, with the pharmacological characteristics of mu-opioid receptors, including high affinity for enkephalins and beta-endorphin but low affinity for dynorphins.</Detail>
      <Keyword>Mu-opioid receptor activity</Keyword>
      <Ontology_ID>GO:0004988</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular messenger to initiate a change in cell activity.</Detail>
      <Keyword>Receptor activity</Keyword>
      <Ontology_ID>GO:0004872</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>152</Position>
      <Original>Asn</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>66</Position>
      <Original>Ser</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>265</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>274</Position>
      <Original>Asp</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>260</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>63</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>147</Position>
      <Original>Ser</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>40</Position>
      <Original>Asn</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>6</Position>
      <Original>Ala</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process which stops, prevents, or reduces the frequency, rate or extent of cAMP-mediated signaling, a series of molecular signals in which a cell uses cyclic AMP to convert an extracellular signal into a response.</Detail>
      <Keyword>Negative regulation of cAMP-mediated signaling</Keyword>
      <Ontology_ID>GO:0043951</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.</Detail>
      <Keyword>Positive regulation of nitric oxide biosynthetic process</Keyword>
      <Ontology_ID>GO:0045429</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a Wnt protein from a cell or group of cells.</Detail>
      <Keyword>Negative regulation of Wnt protein secretion</Keyword>
      <Ontology_ID>GO:0061358</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand, followed by the activation of phospholipase C and the subsequent release of inositol trisphosphate.</Detail>
      <Keyword>Activation of phospholipase C activity by G-protein coupled receptor protein signaling pathway coupled to IP3 second messenger</Keyword>
      <Ontology_ID>GO:0007200</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of N-methyl-D-aspartate selective glutamate receptor activity.</Detail>
      <Keyword>Regulation of N-methyl-D-aspartate selective glutamate receptor activity</Keyword>
      <Ontology_ID>GO:2000310</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of nitric oxide.</Detail>
      <Keyword>Negative regulation of nitric oxide biosynthetic process</Keyword>
      <Ontology_ID>GO:0045019</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of behavior, the specific actions or reactions of an organism in response to external or internal stimuli.</Detail>
      <Keyword>Regulation of behavior</Keyword>
      <Ontology_ID>GO:0050795</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process which activates, maintains or increases the frequency, rate or extent of cAMP-mediated signaling, a series of molecular signals in which a cell uses cyclic AMP to convert an extracellular signal into a response.</Detail>
      <Keyword>Positive regulation of cAMP-mediated signaling</Keyword>
      <Ontology_ID>GO:0043950</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of events required for an organism to receive a painful stimulus, convert it to a molecular signal, and recognize and characterize the signal. Pain is medically defined as the physical sensation of discomfort or distress caused by injury or illness, so can hence be described as a harmful stimulus which signals current (or impending) tissue damage. Pain may come from extremes of temperature, mechanical damage, electricity or from noxious chemical substances. This is a neurological process.</Detail>
      <Keyword>Sensory perception of pain</Keyword>
      <Ontology_ID>GO:0019233</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the concentration of calcium ions in the cytosol.</Detail>
      <Keyword>Elevation of cytosolic calcium ion concentration</Keyword>
      <Ontology_ID>GO:0007204</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation).</Detail>
      <Keyword>Cellular response to stress</Keyword>
      <Ontology_ID>GO:0033554</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.</Detail>
      <Keyword>Positive regulation of ERK1 and ERK2 cascade</Keyword>
      <Ontology_ID>GO:0070374</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of neurogenesis, the origin and formation of neurons.</Detail>
      <Keyword>Positive regulation of neurogenesis</Keyword>
      <Ontology_ID>GO:0050769</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in the behavior of an organism as a result of an ethanol stimulus.</Detail>
      <Keyword>Behavioral response to ethanol</Keyword>
      <Ontology_ID>GO:0048149</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The series of molecular signals generated as a consequence of a G-protein coupled receptor binding to its physiological ligand.</Detail>
      <Keyword>G-protein coupled receptor protein signaling pathway</Keyword>
      <Ontology_ID>GO:0007186</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the concentration of calcium ions in the cytodol.</Detail>
      <Keyword>Reduction of cytosolic calcium ion concentration</Keyword>
      <Ontology_ID>GO:0051481</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or reduces the rate or extent of cell proliferation.</Detail>
      <Keyword>Negative regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008285</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions via a voltage-gated calcium channel.</Detail>
      <Keyword>Negative regulation of calcium ion transport via voltage-gated calcium channel activity</Keyword>
      <Ontology_ID>GO:0051927</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal, e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light, and ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell, and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.</Detail>
      <Keyword>Signal transduction</Keyword>
      <Ontology_ID>GO:0007165</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>365</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>372</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>396</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>168</Position>
      <PTM_Type>Phosphotyrosine</PTM_Type>
    </PTM>
    <PTM>
      <Position>377</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCPPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP</Protein_Seq>
    <DNA_Seq>GGAATTCCGGCTATAGGCAGAGGAGAATGTCAGATGCTCAGCTCGGTCCCCTCCGCCTGACGCTCCTCTCTGTCTCAGCCAGGACTGGTTTCTGTAAGAAACAGCAGGAGCTGTGGCAGCGGCGAAAGGAAGCGGCTGAGGCGCTTGGAACCCGAAAAGTCTCGGTGCTCCTGGCTACCTCGCACAGCGGTGCCCGCCCGGCCGTCAGTACCATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCAAGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAACCTGTCCGACCCATGCGGTCCGAACCGCACCAACCTGGGCGGGAGAGACAGCCTGTGCCCTCCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTGTGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAGATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACCAGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATCCTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTCTGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTCCGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATTGGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACACTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTCGTGAAGATCTGTGTTTTCATCTTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGCCTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATCACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATTTACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGGCACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTTCTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATTGAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAATACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCCTAACAGGGTCTCATGCCATTCCGACCTTCACCAAGCTTAGAAGCCACCATGTATGTGGAAGCAGGTTGCTTCAAGAATGTGTAGGAGGCTCTAATTCTCTAGGAAAGTGCCTACTTTTAGGTCATCCAACCTCTTTCCTCTCTGGCCACTCTGCTCTGCACATTAGAGGGACAGCCAAAAGTAAGTGGAGCATTTGGAAGGAAAGGAATATACCACACCGAGGAGTCCAGTTTGTGCAAGACACCCAGTGGAACCAAAACCCATCGTGGTATGTGAATTGAAGTCATCATAAAAGGTGACCCTTCTGTCTGTAAGATTTTATTTTCAAGCAAATATTTATGACCTCAACAAAGAAGAACCATCTTTTGTTAAGTTCACCGTAGTAACACATAAAGTAAATGCTACCTCTGATCAAAGCACCTTGAATGGAAGGTCCGAGTCTTTTTAGTGTTTTTGCAAGGGAATGAATCCATTATTCTATTTTAGACTTTTAACTTCAACTTAAAATTAGCATCTGGCTAAGGCATCATTTTCACCTCCATTTCTTGGTTTTGTATTGTTTAAAAAAAATAACATCTCTTTCATCTAGCTCCATAATTGCAAGGGAAGAGATTAGCATGAAAGGTAATCTGAAACACAGTCATGTGTCANCTGTAGAAAGGTTGATTCTCATGCACTNCAAATACTTCCAAAGAGTCATCATGGGGGATTTTTCATTCTTAGGCTTTCAGTGGTTTGTTCCTGGAATTC</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Central nervous system</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>OPRM1</Gene_Name>
    <Gene_Alias>MOR1</Gene_Alias>
    <Gene_ID>4988</Gene_ID>
    <Genbank_ACCN>NM_000914</Genbank_ACCN>
    <Protein_ACCN>NP_000905</Protein_ACCN>
    <HGNC_ID>8156</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/4988</Gene_URL>
    <UCSC_ID>uc011efi.2</UCSC_ID>
    <EMBL_ID>ENSG00000112038</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P21333</Uniprot_ID>
      <Gene_Name>FLNA</Gene_Name>
      <EBI_ID>EBI-350432</EBI_ID>
      <PPI_EBI_URL>EBI-2624570,EBI-350432</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Somatoform Disorder</Disease_Name>
      <Disease_Detail>Somatoform Disorder</Disease_Detail>
      <Disease_DB>SMT006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/somatoform_disorder?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Hemiplegic Migraine</Disease_Name>
      <Disease_Detail>Familial Hemiplegic Migraine</Disease_Detail>
      <Disease_DB>FML023</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_hemiplegic_migraine?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Complex Partial Epilepsy</Disease_Name>
      <Disease_Detail>Complex Partial Epilepsy</Disease_Detail>
      <Disease_DB>CMP006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/complex_partial_epilepsy?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Opioid Abuse</Disease_Name>
      <Disease_Detail>Opioid Abuse</Disease_Detail>
      <Disease_DB>OPD001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/opioid_abuse?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Opiate Dependence</Disease_Name>
      <Disease_Detail>Opiate Dependence</Disease_Detail>
      <Disease_DB>OPT003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/opiate_dependence?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Neonatal Abstinence Syndrome</Disease_Name>
      <Disease_Detail>Neonatal Abstinence Syndrome</Disease_Detail>
      <Disease_DB>NNT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/neonatal_abstinence_syndrome?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Morphine Dependence</Disease_Name>
      <Disease_Detail>Morphine Dependence</Disease_Detail>
      <Disease_DB>MRP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/morphine_dependence?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Withdrawal Disorder</Disease_Name>
      <Disease_Detail>Withdrawal Disorder</Disease_Detail>
      <Disease_DB>WTH001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/withdrawal_disorder?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Shipyard Eye</Disease_Name>
      <Disease_Detail>Shipyard Eye</Disease_Detail>
      <Disease_DB>SHP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/shipyard_eye?search=OPRM1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hemiplegic Migraine</Disease_Name>
      <Disease_Detail>Hemiplegic Migraine</Disease_Detail>
      <Disease_DB>HMP006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hemiplegic_migraine?search=OPRM1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Model of mu-type opioid receptor</PDB_Title>
      <PDB_ID>ASD03180000_1</PDB_ID>
      <Resolution>-1.0</Resolution>
      <Has_Ligand>No</Has_Ligand>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko05032</Pathway_ID>
      <Pathway_Title>Morphine addiction</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Substance dependence</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05032</Pathway_ID>
      <Pathway_Title>Morphine addiction</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Substance dependence</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05032</Pathway_ID>
      <Pathway_Title>Morphine addiction</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Substance dependence</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05032</Pathway_ID>
      <Pathway_Title>Morphine addiction</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Substance dependence</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04915</Pathway_ID>
      <Pathway_Title>Estrogen signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05032</Pathway_ID>
      <Pathway_Title>Morphine addiction</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Substance dependence</Pathway_Subclass>
    </Network>
  </Network_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD03180001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03180002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03180003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03180004</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03180005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>